Business Wire

GALDERMA

Share
Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Galderma today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis. Nemolizumab is a first-in-class investigational monoclonal antibody specifically designed to inhibit IL-31 signaling to provide safe and rapid relief from the most burdensome symptom of both skin conditions: itch.1-7

The U.S. FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Priority Review is granted for medicines that would significantly improve the treatment, diagnosis or prevention of serious conditions.

The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis. Galderma is planning for multiple regulatory submissions in 2024.

“The relentless itch experienced by many people living with prurigo nodularis and atopic dermatitis has a significant impact on their overall quality of life. We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. We are one step closer to delivering this innovative solution to those in need and look forward to the outcomes of these filing decisions.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

The regulatory submissions of nemolizumab in prurigo nodularis are based on data from the phase III OLYMPIA clinical trial program, which evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in patients with prurigo nodularis.8,9

Results from the OLYMPIA program demonstrated nemolizumab’s ability to rapidly improve itch, clear skin nodules and reduce sleep disturbance.

In the OLYMPIA program, patients treated with nemolizumab monotherapy showed clinically and statistically significant improvements in both primary endpoints compared to placebo after 16 weeks of treatment:10,11

  • More than half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity, as measured by the peak-pruritus numerical rating scale (PP-NRS; 8% and 56% in OLYMPIA 1 and 2, respectively, compared to 17% and 21% in the placebo groups; p<0.0001).
  • On average, a third of nemolizumab-treated patients reached clearance or almost-clearance of skin lesions, when assessed using the investigator’s global assessment (IGA) score (26% and 38% in OLYMPIA 1 and 2, respectively, compared to 7% and 11% in the placebo groups; p<0.0001).

The trials also met all key secondary endpoints confirming rapid onset of action on itch and sleep disturbance within four weeks of treatment initiation:

  • 41% of nemolizumab-treated patients achieved an at least four-point reduction in itch in both the OLYMPIA 1 and 2 studies, as measured by the PP-NRS score, compared to 6% and 8% in the placebo groups (p<0.0001), respectively.
  • In OLYMPIA 2, nearly four times as many patients in the nemolizumab-treated group (37%) versus placebo (10%) achieved significant and clinically meaningful improvements in sleep disturbance, as measured by a four-point improvement on the sleep disturbance numerical rating scale (SD-NRS; p<0.0001).

The phase III OLYMPIA clinical trial program is the largest clinical trial program conducted in prurigo nodularis to date, with more than 500 patients enrolled, and the only one to include a long-term extension study.

The regulatory submissions of nemolizumab in atopic dermatitis are based on data from the phase III ARCADIA clinical trial program, which evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in adolescents and adults with moderate to severe atopic dermatitis.12,13

In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Both ARCADIA trials showed clinically and statistically significant improvements in co-primary endpoints, compared to placebo, after 16 weeks of treatment:14

  • More than a third of nemolizumab-treated patients reached clearance or almost-clearance of skin lesions when assessed using the IGA score (36% and 38% in ARCADIA 1 and 2, respectively, compared to 25% and 26% in the placebo groups; p<0.001).
  • More than 40% of nemolizumab-treated patients achieved a 75% reduction in the Eczema Area and Severity Index (44% and 42% in ARCADIA 1 and 2, respectively, compared to 29% and 30% in the placebo groups; p<0.001).

The trials also met all key secondary endpoints confirming rapid onset of action on itch and sleep disturbance, with statistically significant and clinically meaningful improvements observed as early as one week after treatment initiation. Results at week 16 showed:

  • Nearly half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity as measured by the PP-NRS score (49% and 48% in ARCADIA 1 and 2, respectively, compared to 21% in the placebo groups; p<0.0001, MI-MAR analysis).
  • 44% and 38% of nemolizumab-treated patients in ARCADIA 1 and 2, respectively, achieved an at least four-point reduction in sleep disturbance as measured by the SD-NRS score (compared to 22% and 20% in the placebo group; p<0.001, MI-MAR analysis).

Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.10,11,14

About prurigo nodularis
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.5,15-16 Prurigo nodularis is an underrecognized and underdiagnosed skin disease.15,17

About the OLYMPIA phase III clinical trial program
The OLYMPIA program included two identical, pivotal phase III clinical trials which enrolled 560 patients – OLYMPIA 1 and OLYMPIA 2.8,9 These global, randomized, double-blind, placebo-controlled phase III clinical trials assessed the efficacy and safety of nemolizumab monotherapy compared with placebo in patients at least 18 years of age with moderate-to-severe prurigo nodularis after a 16- or 24-week treatment period for OLYMPIA 2 and OLYMPIA 1, respectively.8,9 The two phase III OLYMPIA trials met all primary and key secondary endpoints.10,11 Results showed that treatment with nemolizumab monotherapy resulted in significant and clinically meaningful improvements on itch, sleep disturbance and skin lesions in adult patients with prurigo nodularis, with early and sustained improvements on itch observed by week four.10,11

About atopic dermatitis
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions.19,20 It impacts more than 230 million people worldwide and is the most common inflammatory skin disease.19

About the ARCADIA phase III clinical trial program
The ARCADIA program included two identical, pivotal phase III clinical trials which enrolled more than 1,700 patients – ARCADIA 1 and ARCADIA 2.12,13 These global, randomized, multicenter, double-blind, placebo-controlled phase III clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks compared to placebo (both administered with background topical corticosteroid therapy or topical calcineurin inhibitors).12,13 The trials were conducted in adolescent (12 years and over) and adult patients with moderate to severe atopic dermatitis for an initial treatment phase of 16 weeks, followed by a maintenance treatment phase for up to 48 weeks.12,13 The two phase III ARCADIA trials met their co-primary endpoints and all key secondary endpoints, demonstrating that nemolizumab rapidly and significantly improves itch, skin lesions and sleep disturbance in patients with moderate to severe atopic dermatitis.14

About nemolizumab
Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd., and subsequently licensed to Galderma in 2016 worldwide, except Japan and Taiwan. In Japan, nemolizumab is approved for the treatment of pruritus associated with atopic dermatitis and is in development for prurigo nodularis. Nemolizumab is under regulatory review for the treatment of patients with prurigo nodularis and moderate to severe atopic dermatitis with the U.S. Food and Drug Administration and European Medicines Agency.

About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

  1. Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284. doi:10.1111/ced.14722
  2. Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347. doi:10.1016/j.anai.2018.07.006
  3. Bağci IS and Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858-866. doi:10.1016/j.jaci.2017.10.045
  4. Dillon SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [published correction appears in Nat Immunol. 2005;6(1):114]. Nat Immunol. 2004;5(7):752-760. doi: 10.1038/ni1084
  5. Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi:10.1111/jdv.14570
  6. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi:10.1016/j.jaci.2019.08.013
  7. Halvorsen JA, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014;134(7):1847-1854. doi:10.1038/jid.2014.70
  8. ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN). Available online: https://clinicaltrials.gov/study/NCT04501679. Last accessed February 2024
  9. ClinicalTrials.Gov. An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis. Available online: https://clinicaltrials.gov/study/NCT04501666 Last accessed February 2024
  10. Kwatra SG, et al. Placebo-controlled phase III trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. DOI: 10.1056/NEJMoa2301333
  11. Ständer S, et al. Nemolizumab monotherapy improves itch and skin lesions in patients with moderate-to-severe prurigo nodularis: Results from a global phase 3 trial (OLYMPIA 1). Late-breaking abstract presented at EADV 2023.
  12. ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis. Available online: https://clinicaltrials.gov/study/NCT03989349. Last accessed February 2024
  13. ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis. Available online: https://clinicaltrials.gov/study/NCT03985943 Last accessed February 2024
  14. Silverberg J, et al. Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two identical phase 3 multinational studies (ARCADIA 1 and ARCADIA 2). Late-breaking abstract presented at EADV 2023
  15. Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi:10.1016/j.jaad.2020.04.183
  16. Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi:10.1097/itx.0000000000000042
  17. Kwatra SG, et al. Patient journey and the burden of systemic comorbidities and sequalae in prurigo nodularis. J Drugs Dermatol. 2023;22(12): 12-14. doi:10.36849/JDD.SF365502
  18. Langan SM, et al. Atopic dermatitis [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1
  19. Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213155885/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

C5 Capital Partners with Ukraine’s Brave1 Accelerator to Advance Ukraine’s Defense Innovation4.10.2024 17:46:00 CEST | Press release

C5 Capital, a specialist venture capital firm based in Washington DC and London announces a strategic partnership with Brave1, Ukraine’s premier defense technology accelerator. This collaboration will support Ukraine’s innovative tech startups, accelerating the development and application of critical technologies for the defense of Ukraine against Russian aggression. Brave1 leads Ukraine’s defense innovation ecosystem. Since its launch, the accelerator has evaluated more than 2,600 cutting-edge defense-focused innovations. This remarkable achievement has established Ukraine as emerging global leader in defense technology and innovation. C5 Capital’s partnership will provide investment capital and strategic expertise needed to help Ukrainian founders grow and scale their defense startups, whose innovations are already being tested and deployed in battlefield conditions. “C5 Capital’s strategic partnership with Brave1 is focused on empowering Ukraine’s courageous founders, who are buildi

TXOne Networks Expands Edge Series of OT-Native Network Security Appliances4.10.2024 10:49:00 CEST | Press release

The product family is supercharged with new models and a powerful firmware upgrade. TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced Version 2.1 of its Edge series of networking security appliances. designed to protect industrial processes and infrastructure without disrupting operations. This update enhances network resilience and adaptability across a wider range of industrial verticals. “Our Edge series is specifically engineered for the complexities of OT networks, where traditional IT cybersecurity solutions fall short,” said Dr. Terence Liu, CEO of TXOne Networks. “With version 2.1, we’ve elevated the Edge product line to address the unique challenges faced by OT environments—where disruption isn’t an option. This release underscores our commitment to delivering robust, adaptable security that not only meets current demands but anticipates the evolving needs of industrial operations.” TXOne Networks collaborates with manufacturers and critical in

WELOCK and ApartX Ink Key China-Kazakhstan Digital Trade Agreement at Global Digital Trade Expo4.10.2024 03:54:00 CEST | Press release

Signing Ceremony of China-Kazakhstan Digital Trade Key Project by WELOCK and ApartX in Global Digital Trade Expo On September 25th, the 3rd Global Digital Trade Expo “Digital Trade Night” was held in Hangzhou. The event highlighted important digital trade projects between China and Kazakhstan, injecting constant momentum into economic and trade cooperation between the two sides. During the event, the much-anticipated signing ceremony for the “China-Kazakhstan Digital Trade Key Project” was officially launched. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003595967/en/ (Photo: Business Wire) Important witnesses of the signing ceremony included: Zhaslan Madiyev (Minister) Ministry of Digital Development, Innovations and Aerospace Industry of the Republic of Kazakhstan Yao Gaoyuan Mayor of Hangzhou Avazhan Mukanova (Director of the Department of International Cooperation) Ministry of Digital Development, Innovations and Ae

Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art3.10.2024 18:01:00 CEST | Press release

Saudi traditional arts are set to reach new global audiences as the Royal Institute of Traditional Arts (Wrth) participates in the Saudi Cultural Week in Greece from September 27 to October 1. The event, titled “The Heritage of Two Cultures," explores Saudi heritage through the lens of "Al-Qatt Al-Asiri" art. Wrth offers a series of interactive workshops, including a highlight on the creation of natural dyes and gypsum carving arts with workshops and hands-on community artworks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003645976/en/ Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art (Photo: AETOSWire) As part of Culture Week, five talented Saudi artists lead interactive workshops showcasing the art of gypsum carving with traditional ‘Asiri’ patterns. This unique art form gained international recognition after being inscribed on UNESCO's Intangible Cultural Herit

Experience the Future of Smarter AI for All at Lenovo’s Tenth Annual Global Tech World Event3.10.2024 15:40:00 CEST | Press release

The flagship event showcases Lenovo’s comprehensive portfolio of AI solutions, services, and devices with featured sessions from global leaders at Lenovo, AMD, Intel, Microsoft, NVIDIA, and more On October 15, 2024, Lenovo will host its annual global innovation event, Tech World, in Bellevue, Washington. This marks the 10th consecutive year of the event and reflects a decade of innovation and transformation from the company. This year’s event will explore how Lenovo is delivering on the promise of artificial intelligence (AI) with end-to-end solutions fueling its mission of Smarter AI for All. Technology featured will include ground-breaking AI for Good projects, hybrid AI to empower both individuals and enterprises, and proven ways to fast-track and deploy generative AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003339216/en/ What's next for AI? Join us October 15, 2024 at #LenovoTechWorld to hear top industry leade

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye